United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
Last trade$579.52
Day change-$8.365 (-1.42%)
Day range$575.99 – $590.35
Volume154,895
Market cap$25.04B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$25.04B
Price / earnings
20.34×
Price / book
3.99×
Price / sales
7.85×
EV / sales
7.48×
EV / EBITDA
16.83×
Profitability
Earnings per share
$28.90
Return on assets
17.5%
Return on equity
19.61%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.61×
Quick ratio
4.29×
Cash ratio
1.9×
Cash flow
Price / cash flow
17.51×
Price / free cash flow
28.87×
Free cash flow
$867.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for UTHR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$832.5M
$783.3M
$781.5M
$790.2M
$799.5M
$798.6M
$794.4M
$735.9M
Cost of revenue
$99.1M
$99.5M
$133.4M
$103.4M
$100.9M
$87.6M
$92.5M
$75.9M
Gross profit
$733.4M
$683.8M
$648.1M
$686.8M
$698.6M
$711M
$701.9M
$660M
Selling, general and administrative
$146.4M
$206.7M
$184.1M
$190.6M
$182.6M
$212.5M
$170.1M
$168.5M
Research and development
$279.2M
$146.3M
$138.2M
$139.5M
$127.5M
$134M
$149M
$133.8M
Total operating expenses
$425.6M
$353M
$322.3M
$330.1M
$310.1M
$346.5M
$319.1M
$302.3M
Operating income
$307.8M
$330.8M
$325.8M
$356.7M
$388.5M
$364.5M
$382.8M
$357.7M
Interest expense
-$2.9M
-$2.9M
-$3M
-$3.1M
-$3M
-$7.3M
-$6.1M
-$7.9M
Income before taxes
$372.8M
$372.7M
$318.3M
$444M
$438M
$408.4M
$423.5M
$396.5M
Income taxes
$114.2M
$39.7M
$43.4M
$79.7M
$99.3M
$98.9M
$101.3M
$95.2M
Net income
$258.6M
$333M
$274.9M
$364.3M
$338.7M
$309.5M
$322.2M
$301.3M
Net income attributable to common shareholders
$258.6M
$333M
$274.9M
$364.3M
$338.7M
$309.5M
$322.2M
$301.3M
EBITDA
$334.2M
$355M
$348.4M
$379.5M
$410.4M
$385.6M
$402.6M
$377.4M
Basic earnings per share
$6.06
$7.82
$6.32
$8.39
$7.73
$6.86
$7.18
$6.73
Diluted earnings per share
$5.71
$7.27
$5.82
$7.69
$7.16
$6.41
$6.63
$6.23
Recent news
Company coverage with links to the original publishers.
In a comparison of two medical-drugs sector stocks, Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) emerges as the better value opportunity for investors compared to United Therapeutics (UTHR). SGIOY holds a Zacks Rank #2 (Buy) with stronger estimate revisions and more attractive valuation metrics, including a lower forward P/E ratio of 11.89 versus UTHR's 23.57, and a superior Value grade of B compared to UTHR's C grade.
Robinson Helicopter Company will showcase its expanded portfolio of manned and unmanned helicopters at European Rotors 2026 in Lyon, France (December 1-3). The exhibition will feature the European debut of the R44 Raven II Utility, R22, and R66 helicopters, along with unmanned systems (HELIUS, SPIRIT, SPARTAN). Robinson will also host a panel discussion on single-engine helicopter safety and operations in European airspace, featuring executives from Robinson, Safran Helicopter Engines, and aviation experts.
Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.
Liquidia Corporation (LQDA) reported Q3 2026 revenues of $225.3M, surging 314.6% year-over-year, with YUTREPIA sales reaching $222.7M, up 31% sequentially. The company achieved record October patient shipments and expanded its prescriber base to 1,300 despite temporary referral disruptions following a settlement with United Therapeutics. Management maintained a 94% gross margin and plans to provide 2027 revenue guidance in January.
United Therapeutics reported Q3 2026 earnings of $5.71 per share, missing the consensus estimate of $5.85, representing a -2.39% surprise. However, the company exceeded revenue expectations with $832.5 million versus the estimate of $783.3 million. The stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical - Drugs industry ranks in the top 41% of Zacks industries.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.